-
Article
Open AccessDiscontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis
While immunotherapy combined with chemotherapy (Chemo-IO) is generally recognized for providing superior outcomes compared to monotherapy (mono-IO), it is associated with a higher incidence of treatment-relate...
-
Article
Open AccessDeep learning model improves tumor-infiltrating lymphocyte evaluation and therapeutic response prediction in breast cancer
Tumor-infiltrating lymphocytes (TILs) have been recognized as key players in the tumor microenvironment of breast cancer, but substantial interobserver variability among pathologists has impeded its utility as...
-
Article
EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer
The emergence of RAS/RAF mutant clone is the main feature of EGFR inhibitor resistance in KRAS wild-type colon cancer. However, its molecular mechanism is thought to be multifactorial, mainly due to cellular h...
-
Article
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
Introduction IMC-001 is a fully human IgG1 monoclonal antibody that binds to human PD-L1 (programmed death-ligand 1). This study evaluated the safety, pharmacokinetics, and pharmacodynamics of IMC-001 in patients...
-
Article
Open AccessAuthor Correction: Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
-
Article
Open AccessDeep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
We hypothesized that a deep-learning algorithm using HE images might be capable of predicting the benefits of adjuvant chemotherapy in cancer patients. HE slides were retrospectively collected from 1343 de-ide...
-
Article
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
Although immune-checkpoint inhibitors have become a new therapeutic option for recurrent/metastatic non-small cell lung cancers (R/M-NSCLC), its clinical benefit in the real-world is still unclear.
-
Article
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
Tumor immunogenicity is driven by various genomic and transcriptomic factors but the association with the overall status of methylation aberrancy is not well established. We analyzed The Cancer Genome Atlas pa...
-
Article
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues
Immune checkpoint inhibitor (ICI) has an emerging role in several types of cancer. However, the mechanisms of acquired resistance (AR) to ICI have not been elucidated yet. To identify these mechanisms, we anal...
-
Article
Open AccessClinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients
Although immune checkpoint inhibitors (ICIs) can induce durable responses in non-small-cell lung cancer (NSCLC) patients, a significant proportion of responders still experience progressive disease after a per...
-
Article
Open AccessProgrammed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer
We investigated the role of PD-L1 in the metabolic reprogramming of non-small cell lung cancer (NSCLC).
-
Article
Open AccessAssociation between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours
Tumour immune microenvironment (TIME) of gastrointestinal stromal tumours (GISTs) is largely unknown.
-
Article
Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma
Lymphopenia in patients with glioblastoma (GBM) is related to treatment as well as disease progression. This retrospective study investigated the prevalence, influencing factors, recoverability, and clinical s...
-
Article
Open AccessPrognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients
The purpose of this study was to evaluate the prognostic impact of major histocompatibility complex (MHC) class I expression and programmed death-ligand 1 (PD-L1) expression in patients with head and neck squa...
-
Article
Open AccessGenomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Immunotherapy has emerged as a promising anti-cancer treatment, however, little is known about the genetic characteristics that dictate response to immunotherapy. We develop a transcriptional predictor of immu...
-
Article
Genetic ablation or pharmacologic inhibition of autophagy mitigated NSAID-associated gastric damages
Non-steroidal anti-inflammatory drug (NSAID)-associated endoplasmic reticulum (ER) stress (a cyclooxygenase-2-independent mechanism) and consequent autophagic cell death are responsible for NSAID-associated ga...
-
Article
Prognostic implication of antitumor immunity measured by the neutrophil–lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer
The neutrophil–lymphocyte ratio (NLR) is associated with a poor prognosis in many cancers but the biological mechanisms involved are unknown. Since cytokines and angiogenic factors (CAFs) are reflected by vari...
-
Article
Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer
Little is known about cytokine and angiogenic factors (CAFs) in gastric cancer (GC) in terms of tumor classification and prognostic value. Here, we aimed to correlate CAF signature with overall survival (OS) i...
-
Article
Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer
Weight loss during chemotherapy is a significant prognostic factor for poor survival in patients with advanced gastric cancer (AGC). However, in most studies, weight loss was measured at the end of chemothera...
-
Article
Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications
In advanced gastric cancer (AGC), HER2 is a validated therapeutic target. However, the metabolic landscape of AGC based on HER2 status has not been reported. Furthermore, the prognostic value of HER2 in AGC is...
